Stephan Jackman, developer of a new formulation of lithium, discusses the use of lithium in different populations, potential benefits in reducing dementia and suicide rates, lifestyle factors impacting lithium levels, and a new formulation called LiPerSAL aiming to improve treatment with minimized side effects.
Lithium is a first-line treatment for bipolar disorder that has fewer side effects and higher patient adherence compared to atypical antipsychotics.
A new formulation of lithium, called LiPerSAL, has been developed to enhance its safety and effectiveness, potentially reducing physical side effects and being applicable to various mental health conditions.
Deep dives
Lithium's effectiveness in treating bipolar disorder
Lithium has become a first-line treatment for the early stages of bipolar disorder as it can help patients stay well, function better, and have a longer lifespan. Despite not having the same brand recognition as atypical antipsychotics in treating bipolar depression, lithium tends to have fewer side effects and higher patient adherence. Extended-release lithium is better tolerated than instant release, particularly regarding tremors. However, long-term lithium use does double the risk of developing Stage 3 renal failure, so close monitoring and consultation with a renal specialist are crucial.
Lithium use in special populations
Lithium can be safely used during the postpartum period for women with bipolar disorder, but close monitoring of lithium levels in breastfeeding infants is essential. Postpartum psychosis, which occurs in about 1 in 1000 births, has been linked to bipolar disorder, and lithium has the best evidence for preventing relapse and providing prophylaxis in this condition. Regarding age, lithium use is safe and appropriate in both younger and older populations. For older patients, lower lithium levels are recommended, with specific dosage ranges provided.
New formulation and potential benefits of lithium
A new branded formulation of lithium, called LiPerSAL, has been developed to enhance its safety and effectiveness. This formulation combines lithium with peryline and salicylate, allowing more of it to cross the blood-brain barrier and enter the central nervous system. By lowering serum levels by 20%, LiPerSAL can potentially reduce physical side effects. This formulation is being developed for potential use in Alzheimer's disease, PTSD, major depression, and bipolar disorder. Clinical trials are underway to further evaluate its efficacy and safety.
We interview Stephan Jackman, whose company is developing a new formulation of lithium, and bring updates on lithium in younger, older, and peripartum patients.
Chris Aiken, MD, and Kellie Newsome, PMHNP have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.
Get the Snipd podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share & Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered podcast player
Listen to all your favourite podcasts with AI-powered features
Discover highlights
Listen to the best highlights from the podcasts you love and dive into the full episode